"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04573270","Mesenchymal Stem Cells for the Treatment of COVID-19",,"Completed","No Results Available","Covid19|Prophylaxis","Biological: PrimePro|Other: Placebo","Survival Rates|Contraction Rates","Thomas Advanced Medical LLC|HeartStem Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pro00043080","April 24, 2020","August 20, 2020","September 1, 2020","October 5, 2020",,"October 5, 2020","Southern California Hospital at Culver City / Southern California Hospital at Hollywood, Culver City, California, United States",,"https://ClinicalTrials.gov/show/NCT04573270"
2,"NCT04684602","Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions",,"Recruiting","No Results Available","Autoimmune Diseases|Cardiovascular Disorders|Diabetes Complications|Integumentary Disease|Musculoskeletal Disorders|Neurodegenerative Disorders|Neurologic Disorders|Pulmonary Disorders|Sexual Dysfunction|Urologic Disorders|Viral Illness","Biological: PrimePro™/ PrimeMSK™","Assessment of quality of life (QOL) via 36-Item Short Form Survey (SF-36) change from baseline at 6 and 12 months.|Assessment of disabilities of arm, shoulder, hand via DASH Questionnaire change from baseline at 6 and 12 months.|Assessment of erectile function via International Index of Erectile Function (IIEF-5) change from baseline at 6 and 12 months.|Assessment of COPD via Clinical Chronic Obstructive Pulmonary Disease Questionnaire change from baseline at 6 and 12 months.|Assessment of mental state via Mini Mental State Examination (MMSE) change from baseline at 6 and 12 months.|Assessment of interstitial cystitis via O'Leary/Sant Questionnaire change from baseline at 6 and 12 months.|Assessment of back pain via Oswestry Low Back Pain Disability Questionnaire change from baseline at 6 and 12 months.|Assessment of osteoarthritis via Western Ontario and McMaster Osteoarthritis Index (WOMAC) change from baseline at 6 and 12 months.","Thomas Advanced Medical LLC|HeartStem Institute|NuStem","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","5000","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICSS-2020-032","July 9, 2020","July 9, 2030","December 9, 2030","December 24, 2020",,"April 29, 2022","Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites, Culver City, California, United States",,"https://ClinicalTrials.gov/show/NCT04684602"
